EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: A real-world study in China
J Xu, B Jin, T Chu, X Dong, H Yang, Y Zhang, D Wu… - Lung cancer, 2016 - Elsevier
Introduction There are a number of uncommon EGFR mutations whose associations with
TKIs are not well clarified. Here, we summarize the clinical data of patients with multiple …
TKIs are not well clarified. Here, we summarize the clinical data of patients with multiple …
[HTML][HTML] Uncommon EGFR mutations in a cohort of Chinese NSCLC patients and outcomes of first-line EGFR-TKIs and platinum-based chemotherapy
J Shi, H Yang, T Jiang, X Li, C Zhao… - Chinese Journal of …, 2017 - ncbi.nlm.nih.gov
Objective Data on the clinical activity of epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors (TKIs) in patients with non-small-cell lung cancer (NSCLC) and uncommon …
kinase inhibitors (TKIs) in patients with non-small-cell lung cancer (NSCLC) and uncommon …
Efficacy analysis of tyrosine kinase inhibitors on rare non-small cell lung cancer patients harboring complex EGFR mutations
L Peng, ZG Song, SC Jiao - Scientific reports, 2014 - nature.com
The efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI) in
patients with non-small cell lung cancer (NSCLC) is related to EGFR mutations. Although the …
patients with non-small cell lung cancer (NSCLC) is related to EGFR mutations. Although the …
Epidermal growth factor receptor tyrosine kinase inhibitors for non‐small cell lung cancer harboring uncommon EGFR mutations: Real‐world data from Taiwan
JWC Chang, CY Huang, YF Fang, CF Chang… - Thoracic …, 2023 - Wiley Online Library
Background Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) are the
standard treatment for patients with non‐small cell lung cancer (NSCLC) harboring EGFR …
standard treatment for patients with non‐small cell lung cancer (NSCLC) harboring EGFR …
[HTML][HTML] Association between EGFR exon 19 or exon 21 mutations and survival rates after first‑line EGFR‑TKI treatment in patients with non‑small cell lung cancer
H Jiang, M Zhu, Y Li, Q Li - Molecular and clinical …, 2019 - spandidos-publications.com
Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR‑TKI) is the first‑line
treatment for patients with advanced non‑small‑cell lung cancer (NSCLC) who have an …
treatment for patients with advanced non‑small‑cell lung cancer (NSCLC) who have an …
Tyrosine Kinase Inhibitor Activity in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Retrospective International Cohort Study (UpSwinG)
Background Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) are
standard of care for patients with EGFR mutation-positive non–small-cell lung cancer …
standard of care for patients with EGFR mutation-positive non–small-cell lung cancer …
Uncommon mutation types of epidermal growth factor receptor and response to EGFR tyrosine kinase inhibitors in Chinese non-small cell lung cancer patients
K Chen, X Yu, H Wang, Z Huang, Y Xu, L Gong… - Cancer Chemotherapy …, 2017 - Springer
Purpose Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) is the
standard therapy for advanced lung adenocarcinomas with common EGFR mutations …
standard therapy for advanced lung adenocarcinomas with common EGFR mutations …
A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer
HY Tu, EE Ke, JJ Yang, YL Sun, HH Yan, MY Zheng… - Lung Cancer, 2017 - Elsevier
Introduction Patients with non-small cell lung cancer (NSCLC) harboring uncommon
epidermal growth factor receptor (EGFR) mutations are a heterogeneous group exhibiting …
epidermal growth factor receptor (EGFR) mutations are a heterogeneous group exhibiting …
[HTML][HTML] Uncommon EGFR mutations in lung adenocarcinoma: features and response to tyrosine kinase inhibitors
A Brindel, W Althakfi, M Barritault, E Watkin… - Journal of Thoracic …, 2020 - ncbi.nlm.nih.gov
Background EGFR mutant non-small cell lung cancer (NSCLC) is a heterogeneous disease.
The treatment for frequent EGFR mutations relies on tyrosine kinase inhibitors (TKIs); the …
The treatment for frequent EGFR mutations relies on tyrosine kinase inhibitors (TKIs); the …
Outcome of uncommon EGFR mutation positive newly diagnosed advanced non-small cell lung cancer patients: a single center retrospective analysis
S Kate, A Chougule, A Joshi, V Noronha… - Lung Cancer: Targets …, 2019 - Taylor & Francis
Background The significance of uncommon EGFR mutations in newly diagnosed advanced
non-small-cell lung cancer (NSCLC) patients is incompletely known. We aimed to analyze …
non-small-cell lung cancer (NSCLC) patients is incompletely known. We aimed to analyze …